PB Handbook for Psychiatric Trainees
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Psychiatry Advances in Psychiatric Treatment All RCPsych Journals
QUICK SEARCH:   [advanced]


     

Psychiatric Bulletin (2001) 25: 117-118. doi: 10.1192/pb.25.3.117-b
© 2001 The Royal College of Psychiatrists
This Article
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haw, D. C.
Right arrow Articles by Stubbs, M. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Haw, D. C.
Right arrow Articles by Stubbs, M. J.
Psychiatric Bulletin (2001) 25: 117-118
© 2001 The Royal College of Psychiatrists

Correspondence

New BNF maximum recommended dose for haloperidol

Dr Camilla Haw, Consultant Psychiatrist and Mrs Jean Stubbs, Head of Pharmacy

St Andrew's Hospital, Billing Road, Northampton NN1 5DG

The maximum recommended dose for haloperidol has been reduced from 100 mg (rarely 120 mg) to 30 mg a day for oral therapy and from 60 mg to 18 mg a day for intramuscular administration in the latest edition of the British National Formulary (BNF 40; British Medical Association & Royal Pharmaceutical Society, 2000). This dosage change has not been widely publicised; we only became aware of it through a message posted on the UK Psychiatric Pharmacists' website by a pharmacist, Margaret Rotchell. It appears that the changes to the maximum recommended dosage of Serenace (manufactured by Norton Healthcare) were made to the drug's licence back in September 1998 but have not been brought to the attention of doctors and pharmacists.

The dosage change has implications for patients who are receiving haloperidol on a Form 38 or 39, as the dosage they are receiving may no longer be ‘within BNF limits’ and therefore may not be covered by these forms. Inevitably, more patients will now be considered as being on ‘high dose’ antipsychotic therapy and should be the subject of physical monitoring (Thompson, 1994). Strictly speaking, these patients should be made aware that they are now on high dose therapy and this may affect their consent to treatment.

References

BRITISH MEDICAL ASSOCIATION & ROYAL PHARMACEUTICAL SOCIETY OF GREAT BRITAIN (2000) British National Formulary. London & Wallingford: BMJ & Pharmaceutical Press.

THOMPSON, C. (1994) The use of high-dose antipsychotic medication. British Journal of Psychiatry, 164, 448-458.[Free Full Text]





This Article
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haw, D. C.
Right arrow Articles by Stubbs, M. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Haw, D. C.
Right arrow Articles by Stubbs, M. J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Psychiatry Advances in Psychiatric Treatment All RCPsych Journals